NO20044175L - Anvendelse av epotiloner ved behandling av hjernesykdom relatert til proliferative prosesser - Google Patents

Anvendelse av epotiloner ved behandling av hjernesykdom relatert til proliferative prosesser

Info

Publication number
NO20044175L
NO20044175L NO20044175A NO20044175A NO20044175L NO 20044175 L NO20044175 L NO 20044175L NO 20044175 A NO20044175 A NO 20044175A NO 20044175 A NO20044175 A NO 20044175A NO 20044175 L NO20044175 L NO 20044175L
Authority
NO
Norway
Prior art keywords
epothilones
treatment
disease related
brain disease
proliferative processes
Prior art date
Application number
NO20044175A
Other languages
English (en)
Norwegian (no)
Inventor
Ulrich Klar
Werner Skuballa
Bernd Buchmann
Jens Hoffmann
Rosemarie Lichtner
Andrea Rotgeri
Wolfgang Schwede
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27675676&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20044175(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20044175L publication Critical patent/NO20044175L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20044175A 2002-03-01 2004-09-30 Anvendelse av epotiloner ved behandling av hjernesykdom relatert til proliferative prosesser NO20044175L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36106202P 2002-03-01 2002-03-01
EP02004745A EP1340498A1 (en) 2002-03-01 2002-03-01 Use of epothilones in the treatment of brain diseases associated with proliferative processes
PCT/EP2003/002085 WO2003074053A1 (en) 2002-03-01 2003-02-28 Use of epothilones in the treatment of brain diseases associated with proliferative processes

Publications (1)

Publication Number Publication Date
NO20044175L true NO20044175L (no) 2004-12-01

Family

ID=27675676

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044175A NO20044175L (no) 2002-03-01 2004-09-30 Anvendelse av epotiloner ved behandling av hjernesykdom relatert til proliferative prosesser

Country Status (23)

Country Link
US (1) US20040019088A1 (xx)
EP (2) EP1340498A1 (xx)
JP (1) JP2005525360A (xx)
KR (1) KR20040095244A (xx)
CN (1) CN100473381C (xx)
AR (1) AR038712A1 (xx)
AU (1) AU2003215618B2 (xx)
BR (1) BR0308154A (xx)
CA (1) CA2477403A1 (xx)
CR (1) CR7444A (xx)
EC (1) ECSP045340A (xx)
HK (1) HK1079998A1 (xx)
HR (1) HRP20040892A2 (xx)
IL (1) IL163752A0 (xx)
MX (1) MXPA04008450A (xx)
NO (1) NO20044175L (xx)
NZ (1) NZ546617A (xx)
PL (1) PL370768A1 (xx)
RU (1) RU2351330C2 (xx)
UA (1) UA83798C2 (xx)
WO (1) WO2003074053A1 (xx)
YU (1) YU76404A (xx)
ZA (1) ZA200407905B (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
EP1847540A1 (de) 1997-08-09 2007-10-24 Bayer Schering Pharma Aktiengesellschaft Neue Epothilonderivate, Herstellungsverfahren dafür und ihre pharmazeutische Verwendung
CN1340053A (zh) * 1999-02-11 2002-03-13 舍林股份公司 依泊昔酮衍生物、其制备方法及药物用途
AU772750C (en) * 1999-04-30 2005-02-24 Schering Aktiengesellschaft 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
MXPA05002113A (es) 2002-08-23 2005-06-03 Sloan Kettering Inst Cancer Sintesis de epotilonas, intermediarios para ellas, analogos y usos de los mismos.
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DE10331004A1 (de) * 2003-07-03 2005-02-24 Schering Ag Verfahren für die Herstellung von C1-C15-Fragmenten von Epothilonen und deren Derivaten
EP1559447A1 (en) * 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
US20060069136A1 (en) * 2004-09-24 2006-03-30 Ulrich Klar Use of Epothilones in the treatment of bone metastasis
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
EP1700596A1 (en) * 2005-03-09 2006-09-13 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons
DE102007016046A1 (de) * 2007-03-30 2008-10-23 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von Epothilonderivaten durch selektive katalytische Epoxidierung
BRPI0911482A2 (pt) 2008-04-24 2017-08-29 Bristol Myers Squibb Co Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer
US9717803B2 (en) 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
WO2014072482A1 (en) 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
EP2968582B1 (en) 2013-03-15 2020-07-01 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT833828E (pt) * 1995-06-09 2003-02-28 Novartis Ag Derivados de rapamicina
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
NZ337283A (en) * 1997-02-18 2001-02-23 Canji Inc Use of a tumor suppressing nucleic acid which encodes wild type p53 or retinoblastoma proteins and paclitaxel derivative or a polyprenyl-protein transferase inhibitor for the treatment of neoplasms
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
EP1847540A1 (de) * 1997-08-09 2007-10-24 Bayer Schering Pharma Aktiengesellschaft Neue Epothilonderivate, Herstellungsverfahren dafür und ihre pharmazeutische Verwendung
WO1999028324A1 (en) * 1997-12-04 1999-06-10 Bristol-Myers Squibb Company A process for the reduction of oxiranyl epothilones to olefinic epothilones
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
WO1999067253A2 (en) * 1998-06-22 1999-12-29 Novartis Ag Desmethyl epothilones
CA2361278A1 (en) * 1999-02-18 2000-08-24 Ulrich Klar 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
AR023792A1 (es) * 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
WO2001024763A2 (en) * 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
DE10020517A1 (de) * 2000-04-19 2001-10-25 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
AU2001266583A1 (en) * 2000-05-26 2001-12-11 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
GB0013643D0 (en) * 2000-05-31 2000-07-26 Unilever Plc Targeted moieties for use in bleach catalysts
CA2449077A1 (en) * 2001-06-01 2002-12-12 Gregory D. Vite Epothilone derivatives

Also Published As

Publication number Publication date
EP1480643A1 (en) 2004-12-01
US20040019088A1 (en) 2004-01-29
PL370768A1 (en) 2005-05-30
AU2003215618B2 (en) 2009-06-04
KR20040095244A (ko) 2004-11-12
RU2351330C2 (ru) 2009-04-10
BR0308154A (pt) 2005-01-04
CA2477403A1 (en) 2003-09-12
CN1649587A (zh) 2005-08-03
HK1079998A1 (zh) 2006-04-21
RU2004129325A (ru) 2005-07-10
AR038712A1 (es) 2005-01-26
MXPA04008450A (es) 2005-07-13
CR7444A (es) 2005-10-05
WO2003074053A1 (en) 2003-09-12
AU2003215618A1 (en) 2003-09-16
ZA200407905B (en) 2006-04-26
CN100473381C (zh) 2009-04-01
IL163752A0 (en) 2005-12-18
EP1340498A1 (en) 2003-09-03
JP2005525360A (ja) 2005-08-25
ECSP045340A (es) 2004-11-26
UA83798C2 (ru) 2008-08-26
NZ546617A (en) 2007-12-21
HRP20040892A2 (en) 2004-12-31
YU76404A (sh) 2006-08-17

Similar Documents

Publication Publication Date Title
NO20044175L (no) Anvendelse av epotiloner ved behandling av hjernesykdom relatert til proliferative prosesser
CY2015025I1 (el) Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EP1758854A4 (en) PYRROLIDIN-3-YLE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP1807396A4 (en) 2-AMINOPYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
HK1096603A1 (en) Methods of treating an inflammatory-related disease
EP1804794A4 (en) SPIROPIPERIDINE COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
EP1641748A4 (en) INHIBITORS OF BETA-SECRETASE BASED ON N-ALKYL PHENYLCARBOXAMIDE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP1697308A4 (en) BETA-SECRETASE PHENYLAMIDE AND PYRIDYLAMIDE INHIBITORS FOR ALZHEIMER'S DISEASE
EP1855679A4 (en) INHIBITORS OF AMINOMETHYL BETA-SECRETASE IN THE TREATMENT OF ALZHEIMER'S DISEASE
PT1828151E (pt) Derivados de malonamida como inibidores de gama-secretase para o tratamento da doença de alzheimer
CY2018006I1 (el) Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
NO20055820D0 (no) Peptider til anvendelse ved behandling av overvekt
GB0329874D0 (en) Compounds useful for the treatment of diseases
HK1113319A1 (en) Use of docosahexaenoic triglycerides for the treatment of tumorous diseases
SI1685125T1 (sl) Derivati pirola, primerni za zdravljenje proliferativnih bolezni
ATE439843T1 (de) S-mirtazapin zur behandlung von hitzewallungen
GB0320238D0 (en) Treatment of disease
IL184849A0 (en) Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
DE602005017605D1 (de) Pyrrolopyrimidinderivate zur behandlung proliferativer krankheiten
NO20043674L (no) Fremgangsmate for behandling av karbonholdige stoffer
PL1904060T3 (pl) Zastosowanie pochodnych ftalocyjaniny do nie-fotodynamicznego leczenia chorób
EP1613318A4 (en) COMPOUNDS AND ITS USE FOR THE TREATMENT OF DIABETES AND RELATED DISEASES

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application